爱尔兰爵士制药的去纤维钠疗效怎么样？

Irish Jazz Pharmaceuticals is a mixture of single-stranded oligonucleotides with anti-thrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that defibrotide is a safe and effective drug for preventing and treating hepatic veno-occlusive disease (HVOD).

Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ), founded in 2003, is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of pharmaceutical products. Headquartered in Dublin, Ireland, how effective is Irish Jazz Pharmaceuticals’ defibrinated sodium?

A large series of prospective clinical studies included 305 patients with HVOD after HSCT, with a median age of 16 years (0.1-70 years), including 220 patients with sHVOD. The therapeutic dose of defibrotide sodium is 25mg/kg per day, intravenous infusion. Preliminary results show that: the complete response (CR) rate is 30%, and the overall survival (OS) rate 100 days after transplantation is 50%; the CR rate of sHVOD patients is 26%, and the OS rate 100 days after transplantation is 45%; the CR rate of non-sHVOD patients is 39%, and the OS rate 100 days after transplantation is 65%. The CR rates of pediatric and adult patients were 33% and 26%, respectively (P=0.187), and the OS rates 100 days after transplantation were 56% and 44%, respectively (P=0.0277).

For more information about the drugs of Jazz Pharmaceuticals in Ireland, patients can consult the medical companion and travel service for detailed information.

Recommended related hot articles: /newsDetail/92907.html